SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 10/12/18 Intellipharmaceutics Int’l Inc. F-1MEF 10/12/18 5:193K Blueprint/FA |
Document/Exhibit Description Pages Size 1: F-1MEF Registration of Additional Securities HTML 48K 2: EX-5.1 Opinion on Legality HTML 22K 3: EX-5.2 Opinion on Legality HTML 17K 4: EX-23.1 Consents of Experts and Counsel HTML 7K 5: EX-23.2 Consents of Experts and Counsel HTML 8K
Blueprint |
As filed with the Securities and Exchange Commission on October 12,
2018
|
||
|
|
|
|
|
Registration No. 333-
|
|
|
|
|
||
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
||
|
||
FORM F-1
|
||
|
||
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF
1933
INTELLIPHARMACEUTICS
INTERNATIONAL INC.
|
||
|
||
(Exact
name of Registrant as specified in its charter)
|
||
|
||
Not Applicable
|
||
(Translation
of Registrant’s name into
English)
|
||
|
|
|
Canada
|
2834
|
Not Applicable
|
(State
or other jurisdiction of incorporation or
organization)
|
(Primary
Standard Industrial Classification Code Number)
|
(I.R.S.
Employer Identification Number)
|
|
|
|
|
Intellipharmaceutics
International Inc.
30 Worcester Road
Toronto, Ontario
Canada, M9W 5X2
(416) 798-3001
|
|
(Address,
including zip code, and telephone number, including area code, of
Registrant’s principal
executive offices)
|
||
|
|
|
|
Corporation Service Company
1090 Vermont Avenue N.W.
(800) 927-9800
|
|
(Name,
address, and telephone number of agent for service)
|
||
|
|
|
|
With copies to:
|
|
|
|
|
Richard DiStefano, Esq.
Brian North, Esq.
Buchanan Ingersoll & Rooney PC
640 Fifth Avenue
Telephone: (212) 440-4455
Facsimile: (212) 440-4401
|
Tina M. Woodside, Esq.
Gowling WLG (Canada) LLP
Suite 1600, 1 First Canadian Place
100 King Street West
Toronto, Ontario M5X 1G5
Telephone: (416) 369-4584
Facsimile: (416) 862-7661
|
Jeffrey Fessler, Esq.
Sheppard Mullin Richter & Hampton LLP
30 Rockefeller Plaza, 39th Floor
Telephone: (212) 653-8700
Facsimile: (212) 653-8701
|
Title of Each Class of Securities To Be Registered
|
Proposed Maximum Aggregate Offering Price (1) (2) (3)
|
Amount of Registration Fee (2)
|
Units, each Unit
consisting of one common share, no par value (“Common Shares”), and one warrant (“Warrant”) to purchase one Common Share
(3)
|
$1,200,000
|
$145.44
|
(i) Common Shares
included in the Units (4)
|
—
|
—
|
(ii) Warrants
included in the Units (4)
|
—
|
—
|
Pre-Funded Units,
each Pre-Funded Unit consisting of one pre-funded warrant
(“Pre-Funded
Warrant”) to purchase one
Common Share and one Warrant to purchase one Common Share
(3)
|
$1,188,000
|
$143.99
|
(i) Pre-Funded
Warrants included in the Pre-Funded Units (4)
|
—
|
—
|
(ii) Warrants
included in the Pre-Funded Units (4)
|
—
|
—
|
Common Shares
issuable upon exercise of warrants (3)
|
$1,200,000
|
$145.44
|
Common Shares
issuable upon exercise of pre-funded warrants (3)
|
$12,000
|
$1.45
|
Underwriter’s
Warrants (5)
|
|
|
Common Shares
issuable upon exercise of Underwriter’s Warrants (6)
|
$90,000
|
$10.91
|
Total
|
$3,690,000
|
$447.23
|
Exhibit Number
|
Description
|
|
|
|
|
|
|
INTELLIPHARMACEUTICS INTERNATIONAL INC.
|
||
|
|
|
|
|
By:
|
/s/ Dr. Amina
Odidi
|
|
|
|
Dr.
Amina Odidi
|
|
|
|
President,
Chief Operating Officer and Director
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Dr. Isa
Odidi
|
|
Chairman
of the Board of Directors
|
|
|
Dr. Isa
Odidi
|
|
Chief
Executive Officer and Co-Chief Scientific Officer (Principal
Executive Officer)
|
|
|
|
|
|
|
|
/s/ Andrew
Patient
|
|
Chief
Financial Officer
|
|
|
Andrew
Patient
|
|
(Principal Financial and
Accounting Officer)
|
|
|
|
|
|
|
|
/s/ Dr. Amina
Odidi
|
|
President,
Chief Operating Officer, Co-Chief Scientific Officer and
Director
|
|
|
Dr.
Amina Odidi
|
|
|
|
|
|
|
|
|
|
|
|
Director
|
|
|
Kenneth
Keirstead
|
|
|
|
|
|
|
|
|
|
/s/ Bahadur
Madhani
|
|
Director
|
|
|
Bahadur
Madhani
|
|
|
|
|
|
|
|
|
|
|
|
Director
|
|
|
Eldon
R. Smith
|
|
|
|
|
|
|
|
|
|
/s/ Shawn
Graham
|
|
Director
|
|
|
Shawn
Graham
|
|
|
|
|
|
VASOGEN INC.
|
||
|
|
||
|
By:
|
/s/ Dr. Amina
Odidi
|
|
|
|
Name:
Dr. Amina Odidi
|
|
|
|
Title:
President, Chief Operating Officer, Co-Chief Scientific Officer and
Director
|
This ‘F-1MEF’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on / Effective on: | 10/12/18 | |||
10/11/18 | 424B3, 6-K, F-1/A | |||
10/5/18 | 424B3, 6-K, F-1/A, FWP | |||
9/20/18 | F-1 | |||
4/5/12 | ||||
List all Filings |